Data / Drug companies / Chartwell Governmental & Specialty RX, LLC.
Chartwell Governmental & Specialty RX, LLC.: 48 products in the FDA NDC directory, labeler code 68999
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Chartwell Governmental & Specialty RX, LLC. (labeler code 68999) lists 48 products in the FDA National Drug Code Directory, covering 38 finished drugs by generic name. By type: 48 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on April 14, 2025.
The request: Watch Chartwell Governmental & Specialty RX, LLC. (FDA labeler code 68999): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 68999
- Products in commercial distribution
- 48
- Packages
- 71
- Finished drugs by generic name
- 38
- Prescription products
- 48
- Over the counter products
- 0
- Controlled substance products
- Schedule IV 2, Schedule V 1
- Flagged as original packager
- 46 of 46 products that carry the flag
- Started marketing in the last 12 months
- 0
- Earliest marketing start
- April 14, 1971
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 42 | 87.5% |
| Other unapproved drugs | 5 | 10.4% |
| Authorized generics (NDA) | 1 | 2.1% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 48 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Solution | 28 | 58.3% |
| Suspension | 8 | 16.7% |
| Capsule | 5 | 10.4% |
| Syrup | 3 | 6.2% |
| Tablet, film coated | 2 | 4.2% |
| Liquid | 1 | 2.1% |
| Powder, for suspension | 1 | 2.1% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Sucralfate | 68999-106 | Suspension | Generic drugs (ANDA) | April 14, 2025 |
| Phenobarbital | 68999-962 | Solution | Other unapproved drugs | February 13, 2025 |
| Lacosamide Oral Solution | 68999-885 | Solution | Generic drugs (ANDA) | May 15, 2024 |
| Escitalopram Oral Solution | 68999-729 | Solution | Generic drugs (ANDA) | June 12, 2023 |
| Sodium Citrate and Citric Acid | 68999-869 | Solution | Other unapproved drugs | December 8, 2022 |
| Sodium Citrate and Citric Acid | 68999-868 | Solution | Other unapproved drugs | December 8, 2022 |
| Tricitrates | 68999-438 | Solution | Other unapproved drugs | December 8, 2022 |
| Potassium Citrate and Citric Acid | 68999-435 | Solution | Other unapproved drugs | December 8, 2022 |
| Prednisolone | 68999-250 | Solution | Generic drugs (ANDA) | November 20, 2022 |
| Oxcarbazepine | 68999-841 | Suspension | Generic drugs (ANDA) | September 21, 2021 |
| Doxycycline Hyclate | 68999-625 | Tablet, film coated | Generic drugs (ANDA) | July 21, 2021 |
| Acyclovir | 68999-803 | Suspension | Generic drugs (ANDA) | April 23, 2020 |
| Brompheniramine Maleate, Pseudoephedrine Hydrochloride, and Dextromethorphan Hydrobromide | 68999-302 | Syrup | Generic drugs (ANDA) | April 17, 2020 |
| Lactulose | 68999-004 | Solution | Generic drugs (ANDA) | November 23, 2018 |
| Lactulose | 68999-002 | Solution | Generic drugs (ANDA) | November 23, 2018 |
| Atovaquone | 68999-528 | Suspension | Generic drugs (ANDA) | April 28, 2017 |
| Diazepam | 68999-767 | Solution | Generic drugs (ANDA) | June 24, 2016 |
| Memantine Hydrochloride | 68999-943 | Solution | Generic drugs (ANDA) | October 13, 2015 |
| Lamivudine | 68999-706 | Solution | Generic drugs (ANDA) | October 31, 2014 |
| Theophylline | 68999-556 | Solution | Generic drugs (ANDA) | April 13, 2011 |
| Ondansetron Hydrochloride | 68999-555 | Solution | Generic drugs (ANDA) | January 27, 2011 |
| LEVETIRACETAM solution | 68999-548 | Solution | Generic drugs (ANDA) | April 3, 2009 |
| Doxycycline | 68999-417 | Powder, for suspension | Generic drugs (ANDA) | July 16, 2008 |
| Albuterol sulfate | 68999-189 | Syrup | Generic drugs (ANDA) | June 26, 2007 |
| Lidocaine Hydrochloride | 68999-871 | Solution | Generic drugs (ANDA) | February 27, 2007 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.